ARCT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AR

Mkt Cap

$294.2M

Volume

683.51K

Next Earnings

November 9th

Loading chart

AR

ARCTArcturus Therapeutics Holdings Inc. Common Stock

ARCT

Pay with—

Available Balance0.00

AR

Mkt Cap

$320.3M

Volume

683.51K

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and MoreThe global mRNA therapeutics market (excluding COVID-19 applications) is projected to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, with a 63% CAGR. Growth is driven by expanding oncology and rare disease pipelines, advances in lipid nanoparticle delivery, and strategic partnerships. However, challenges include tissue-selective delivery limitations, repeat-dose tolerability concerns, and regulatory complexities. Moderna and BioNTech dominate with approximately 70% of pipeline activity.GlobeNewswire Inc. · Aug 26, 2026

These Are the Only 3 Stocks That Cathie Wood Bought Last WeekCathie Wood's Ark Invest made surprisingly few purchases last week, buying shares in only three companies: Figma, Arcturus Therapeutics, and 10x Genomics. Despite significant declines from their highs, Wood sees value in these growth-stage companies across design software, biotech, and genomics sectors.The Motley Fool · Mar 23, 2026

Cathie Wood Goes Shopping: 3 Stocks She Just BoughtCathie Wood of Ark Invest purchased shares of Robinhood Markets, Netflix, and Arcturus Therapeutics on Wednesday, taking advantage of recent stock price dips and seeing potential growth opportunities in these companies.The Motley Fool · Oct 23, 2025

10 Health Care Stocks With Whale Alerts In Today's SessionMultiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.Benzinga · Sep 29, 2025

Lipid Nanoparticles Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034The Lipid Nanoparticles (LNPs) market is projected to grow from $1 billion in 2024 to $3.5 billion by 2034, driven by increasing demand for mRNA-based therapeutics and advances in drug delivery systems.GlobeNewswire Inc. · Aug 5, 2025

RNA Therapeutics and RNA Vaccines Market Industry Report 2025-2035: Investments in RNA Technologies Surge with USD 2.9 Billion FundingThe global RNA therapeutics and vaccines market is projected to reach USD 940 million by 2035, growing at a CAGR of 68%, driven by advancements in RNA technologies and next-generation therapies.GlobeNewswire Inc. · Jul 18, 2025

Flu RNA Vaccines Market Research Report 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and ChallengesThe global flu RNA vaccines market is expected to grow from $2.78 billion in 2025 to $5.95 billion by 2032, driven by advancements in mRNA technology and the need for rapid adaptation to evolving flu strains. North America leads the market, with notable growth in Europe and Asia-Pacific.GlobeNewswire Inc. · Jun 20, 2025

Synaptics Seeks to Alter the Trajectory of the IoT at Embedded World With Contextual Edge AI and Wireless InnovationsSynaptics is showcasing its latest innovations in Edge AI and wireless connectivity at Embedded World 2025, including a new family of microcontroller units (MCUs) and wireless systems-on-chips (SoCs) designed for ultra-low-power IoT devices with contextually-aware AI and reliable connectivity.GlobeNewswire Inc. · Mar 5, 2025

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccineThe European Commission has approved KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine developed by CSL and Arcturus Therapeutics. KOSTAIVE is the first of its kind to receive approval in Europe and has shown superior immunogenicity and antibody persistence compared to conventional mRNA vaccines.Benzinga · Feb 14, 2025

mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS InsiderThe mRNA therapeutics market is expected to grow significantly, driven by the success of mRNA-based COVID-19 vaccines and the expanding applications of mRNA technology in areas like cancer treatment and infectious diseases.GlobeNewswire Inc. · Dec 8, 2024

to start trading

AR

ARCTArcturus Therapeutics Holdings Inc. Common Stock

ARCT

Pay with—

Available Balance0.00

Your PositionYou don't own any ARCT yet.

Related Tickers

Earnings